Literature DB >> 19243825

Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.

Chie Sotozono1, Mayumi Ueta, Noriko Koizumi, Tsutomu Inatomi, Yuji Shirakata, Zenro Ikezawa, Koji Hashimoto, Shigeru Kinoshita.   

Abstract

PURPOSE: To present a detailed clarification of the symptoms at disease onset of Stevens-Johnson syndrome (SJS) and its more severe variant, toxic epidermal necrolysis (TEN), with ocular complications and to clarify the relationship between topical steroid use and visual prognosis.
DESIGN: Cross-sectional study. PARTICIPANTS: Ninety-four patients with SJS and TEN with ocular complications.
METHODS: A structured interview, examination of the patient medical records, or both addressing clinical manifestations at disease onset were conducted for 94 patients seen at Kyoto Prefectural University of Medicine. Any topical steroid use during the first week at the acute stage also was investigated. MAIN OUTCOME MEASURES: The incidence and the details of prodromal symptoms and the mucosal involvements and the relationship between topical steroid use and visual outcomes.
RESULTS: Common cold-like symptoms (general malaise, fever, sore throat, etc.) preceded skin eruptions in 75 cases, and extremely high fever accompanied disease onset in 86 cases. Acute conjunctivitis and oral and nail involvements were reported in all patients who remembered the details. Acute conjunctivitis occurred before the skin eruptions in 42 patients and simultaneously in 21 patients, whereas only 1 patient reported posteruption conjunctivitis. Visual outcomes were significantly better in the group receiving topical steroids compared with those of the no-treatment group (P<0.00001).
CONCLUSIONS: Acute conjunctivitis occurring before or simultaneously with skin eruptions accompanied by extremely high fever and oral and nail involvement indicate the initiation of SJS or TEN. Topical steroid treatment from disease onset seems to be important for the improvement of visual prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243825     DOI: 10.1016/j.ophtha.2008.12.048

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  40 in total

Review 1.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

2.  A 26-year-old man with ocular complications after adverse reaction to phenytoin.

Authors:  Ritesh Gupta; Vasudha Gupta; Yasser Khan
Journal:  Digit J Ophthalmol       Date:  2016-10-04

Review 3.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

4.  Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome.

Authors:  Young Hoon Hwang; Myung Seung Kang; Kyung O Lim; Sang Mok Lee
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

5.  A case of toxic epidermal necrolysis (ten) with severe chronic ocular complications in a healthy 46-year-old woman.

Authors:  A Voltan; B Azzena
Journal:  Ann Burns Fire Disasters       Date:  2010-06-30

6.  Acute and Chronic Ophthalmic Involvement, Severity, and Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Sunil Ganekal; Ashwini Nagarajappa
Journal:  Korean J Ophthalmol       Date:  2021-02-18

Review 7.  Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.

Authors:  Rohini Arora; Rajesh K Pande; Shikha Panwar; Vivek Gupta
Journal:  Indian J Crit Care Med       Date:  2021-05

8.  Prompt versus delayed amniotic membrane application in a patient with acute Stevens-Johnson syndrome.

Authors:  Jessica B Ciralsky; Kimberly C Sippel
Journal:  Clin Ophthalmol       Date:  2013-05-31

9.  HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications.

Authors:  Mayumi Ueta; Katsushi Tokunaga; Chie Sotozono; Hiromi Sawai; Gen Tamiya; Tsutomu Inatomi; Shigeru Kinoshita
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

Review 10.  Adverse cutaneous drug eruptions: current understanding.

Authors:  W Hoetzenecker; M Nägeli; E T Mehra; A N Jensen; I Saulite; P Schmid-Grendelmeier; E Guenova; A Cozzio; L E French
Journal:  Semin Immunopathol       Date:  2015-11-09       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.